Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

The mesenchymal and myeloid regulation of immunity: Power is nothing without control.

Bronte V.

Semin Immunol. 2018 Feb;35:1-2. doi: 10.1016/j.smim.2018.03.001. No abstract available.

PMID:
29566937
2.

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors.

Sharma MD, Rodriguez PC, Koehn BH, Baban B, Cui Y, Guo G, Shimoda M, Pacholczyk R, Shi H, Lee EJ, Xu H, Johnson TS, He Y, Mergoub T, Venable C, Bronte V, Wolchok JD, Blazar BR, Munn DH.

Immunity. 2018 Jan 16;48(1):91-106.e6. doi: 10.1016/j.immuni.2017.12.014.

PMID:
29343444
3.

Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy.

Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, Scupoli MT, Nishimura MI, Iezzi M, Sartoris S, Bronte V, Ugel S.

Oncotarget. 2017 May 23;8(50):86987-87001. doi: 10.18632/oncotarget.18115. eCollection 2017 Oct 20.

4.

From Oncogene Interference to Neutrophil Immune Modulation.

Bronte V.

Immunity. 2017 Oct 17;47(4):613-615. doi: 10.1016/j.immuni.2017.10.005.

PMID:
29045894
5.

The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO.

Mondanelli G, Ugel S, Grohmann U, Bronte V.

Curr Opin Pharmacol. 2017 Aug;35:30-39. doi: 10.1016/j.coph.2017.05.002. Epub 2017 May 26. Review.

PMID:
28554057
6.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

7.

4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells.

Zilio S, Vella JL, De la Fuente AC, Daftarian PM, Weed DT, Kaifer A, Marigo I, Leone K, Bronte V, Serafini P.

J Immunol. 2017 May 15;198(10):4166-4177. doi: 10.4049/jimmunol.1600833. Epub 2017 Apr 10.

PMID:
28396317
8.

A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells.

Mondanelli G, Bianchi R, Pallotta MT, Orabona C, Albini E, Iacono A, Belladonna ML, Vacca C, Fallarino F, Macchiarulo A, Ugel S, Bronte V, Gevi F, Zolla L, Verhaar A, Peppelenbosch M, Mazza EMC, Bicciato S, Laouar Y, Santambrogio L, Puccetti P, Volpi C, Grohmann U.

Immunity. 2017 Feb 21;46(2):233-244. doi: 10.1016/j.immuni.2017.01.005. Epub 2017 Feb 14.

9.

Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b+ cells that expedite hematopoietic recovery.

Trento C, Marigo I, Pievani A, Galleu A, Dolcetti L, Wang CY, Serafini M, Bronte V, Dazzi F.

Haematologica. 2017 May;102(5):818-825. doi: 10.3324/haematol.2016.155390. Epub 2017 Feb 9.

10.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009. No abstract available.

11.

Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo".

Perico ME, Grasso S, Brunelli M, Martignoni G, Munari E, Moiso E, Fracasso G, Cestari T, Naim HY, Bronte V, Colombatti M, Ramarli D.

Oncotarget. 2016 Nov 8;7(45):74189-74202. doi: 10.18632/oncotarget.12404.

12.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EMC, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004. Erratum in: Cancer Cell. 2016 Oct 10;30(4):651.

13.

Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers.

Bronte V, Tortora G.

Cancer Discov. 2016 Aug;6(8):821-3. doi: 10.1158/2159-8290.CD-16-0682.

14.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

15.

Tumor-Induced Myeloid-Derived Suppressor Cells.

De Sanctis F, Bronte V, Ugel S.

Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.MCHD-0016-2015. Review.

PMID:
27337449
16.

Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.

Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scupoli MT, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S.

Cancer Res. 2016 May 1;76(9):2540-51. doi: 10.1158/0008-5472.CAN-15-2318.

17.

Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.

Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S, Bronte V, Marigo I, Benoit JP.

Biomaterials. 2016 Jul;96:47-62. doi: 10.1016/j.biomaterials.2016.04.010. Epub 2016 Apr 22.

PMID:
27135716
18.

Interfering with CCL5/CCR5 at the Tumor-Stroma Interface.

Bronte V, Bria E.

Cancer Cell. 2016 Apr 11;29(4):437-439. doi: 10.1016/j.ccell.2016.03.019.

19.

Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.

Arina A, Corrales L, Bronte V.

Semin Immunol. 2016 Feb;28(1):54-63. doi: 10.1016/j.smim.2016.01.002. Epub 2016 Feb 10. Review.

PMID:
26872631
20.

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study.

Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S.

Cancer Immunol Immunother. 2016 Feb;65(2):161-9. doi: 10.1007/s00262-015-1782-5. Epub 2016 Jan 4.

21.

Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.

Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A, Mocellin S, Rossi CR, Bronte V, Mandruzzato S.

Oncotarget. 2016 Jan 12;7(2):1168-84. doi: 10.18632/oncotarget.6662.

22.

Immune suppressive mechanisms in the tumor microenvironment.

Munn DH, Bronte V.

Curr Opin Immunol. 2016 Apr;39:1-6. doi: 10.1016/j.coi.2015.10.009. Epub 2015 Nov 21. Review.

23.

Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.

Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosi M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M.

Target Oncol. 2016 Jun;11(3):345-51. doi: 10.1007/s11523-015-0396-3.

PMID:
26566945
24.

Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs).

Mazza EM, Zoso A, Mandruzzato S, Bronte V, Serafini P, Inverardi L, Bicciato S.

Genom Data. 2014 Oct 31;2:389-92. doi: 10.1016/j.gdata.2014.10.018. eCollection 2014 Dec.

25.

Transgenic mice overexpressing arginase 1 in monocytic cell lineage are affected by lympho-myeloproliferative disorders and disseminated intravascular coagulation.

Astigiano S, Morini M, Damonte P, Fraternali Orcioni G, Cassanello M, Puglisi A, Noonan DM, Bronte V, Barbieri O.

Carcinogenesis. 2015 Nov;36(11):1354-62. doi: 10.1093/carcin/bgv129. Epub 2015 Sep 10.

PMID:
26363032
26.

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

Ugel S, De Sanctis F, Mandruzzato S, Bronte V.

J Clin Invest. 2015 Sep;125(9):3365-76. doi: 10.1172/JCI80006. Epub 2015 Sep 1. Review.

27.

CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells.

Zhu Z, Cuss SM, Singh V, Gurusamy D, Shoe JL, Leighty R, Bronte V, Hurwitz AA.

J Immunol. 2015 Oct 1;195(7):3482-9. doi: 10.4049/jimmunol.1401571. Epub 2015 Aug 28.

28.

Monocyte-Derived Suppressor Cells in Transplantation.

Ochando J, Conde P, Bronte V.

Curr Transplant Rep. 2015;2(2):176-183. Review.

29.

GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.

Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, Bronte V, Murray PJ, Ting JP, Zeiser R, Blazar BR.

Blood. 2015 Sep 24;126(13):1621-8. doi: 10.1182/blood-2015-03-634691. Epub 2015 Aug 11.

30.

MDSCs in cancer: Conceiving new prognostic and therapeutic targets.

De Sanctis F, Solito S, Ugel S, Molon B, Bronte V, Marigo I.

Biochim Biophys Acta. 2016 Jan;1865(1):35-48. doi: 10.1016/j.bbcan.2015.08.001. Epub 2015 Aug 6. Review.

PMID:
26255541
31.

Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210.

Noman MZ, Janji B, Hu S, Wu JC, Martelli F, Bronte V, Chouaib S.

Cancer Res. 2015 Sep 15;75(18):3771-87. doi: 10.1158/0008-5472.CAN-15-0405. Epub 2015 Jul 23.

32.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E, Tortora G.

PLoS One. 2015 Jun 18;10(6):e0130142. doi: 10.1371/journal.pone.0130142. eCollection 2015.

33.

DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance.

Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, Yun TJ, Riquelme P, Rastrojo A, Aguado B, Stein-Streilein J, Tanaka M, Zhou L, Zhang J, Lowary TL, Ginhoux F, Park CG, Cheong C, Brody J, Turley SJ, Lira SA, Bronte V, Gordon S, Heeger PS, Merad M, Hutchinson J, Chen SH, Ochando J.

Immunity. 2015 Jun 16;42(6):1143-58. doi: 10.1016/j.immuni.2015.05.009. Epub 2015 Jun 9.

34.

Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.

Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, Cestari T, Ferrari S, Zanovello P, Bronte V, Sartoris S.

Immunology. 2015 Sep;146(1):33-49. doi: 10.1111/imm.12477. Epub 2015 Jun 15.

35.

Critical role of gap junction communication, calcium and nitric oxide signaling in bystander responses to focal photodynamic injury.

Calì B, Ceolin S, Ceriani F, Bortolozzi M, Agnellini AH, Zorzi V, Predonzani A, Bronte V, Molon B, Mammano F.

Oncotarget. 2015 Apr 30;6(12):10161-74.

36.

Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells.

Arina A, Bronte V.

Curr Opin Immunol. 2015 Apr;33:120-5. doi: 10.1016/j.coi.2015.02.006. Epub 2015 Feb 27. Review.

PMID:
25728992
37.

Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer.

Bronte V, Murray PJ.

Nat Med. 2015 Feb;21(2):117-9. doi: 10.1038/nm.3794. No abstract available.

PMID:
25654601
38.

Tumors STING adaptive antitumor immunity.

Bronte V.

Immunity. 2014 Nov 20;41(5):679-81. doi: 10.1016/j.immuni.2014.11.004. Epub 2014 Nov 20.

39.

Complexity and challenges in defining myeloid-derived suppressor cells.

Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S.

Cytometry B Clin Cytom. 2015 Mar;88(2):77-91. doi: 10.1002/cyto.b.21206. Epub 2014 Dec 12. Review.

40.

Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways.

Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ.

Immunity. 2014 Dec 18;41(6):947-59. doi: 10.1016/j.immuni.2014.10.020. Epub 2014 Dec 11.

41.

Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models.

Ricci C, Mota C, Moscato S, D'Alessandro D, Ugel S, Sartoris S, Bronte V, Boggi U, Campani D, Funel N, Moroni L, Danti S.

Biomatter. 2014;4:e955386. doi: 10.4161/21592527.2014.955386.

42.

Complexity and challenges in defining myeloid-derived suppressor cells.

Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S.

Cytometry B Clin Cytom. 2014 Nov 26. doi: 10.1002/cytob.21206. [Epub ahead of print]

43.

Differential control of Mincle-dependent cord factor recognition and macrophage responses by the transcription factors C/EBPβ and HIF1α.

Schoenen H, Huber A, Sonda N, Zimmermann S, Jantsch J, Lepenies B, Bronte V, Lang R.

J Immunol. 2014 Oct 1;193(7):3664-75. doi: 10.4049/jimmunol.1301593. Epub 2014 Aug 25.

44.

Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion.

Zoso A, Mazza EM, Bicciato S, Mandruzzato S, Bronte V, Serafini P, Inverardi L.

Eur J Immunol. 2014 Nov;44(11):3307-19. doi: 10.1002/eji.201444522. Epub 2014 Oct 18.

45.

Tumor cells hijack macrophages via lactic acid.

Bronte V.

Immunol Cell Biol. 2014 Sep;92(8):647-9. doi: 10.1038/icb.2014.67. Epub 2014 Aug 5. No abstract available.

PMID:
25091608
46.

Myeloid-derived suppressor cell heterogeneity in human cancers.

Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V.

Ann N Y Acad Sci. 2014 Jun;1319:47-65. doi: 10.1111/nyas.12469. Review.

PMID:
24965257
47.

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.

Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S.

J Exp Med. 2014 May 5;211(5):781-90. doi: 10.1084/jem.20131916. Epub 2014 Apr 28.

48.

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.

Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, Bronte V, Di Virgilio F, Pistoia V, Raffaghello L.

Cell Death Dis. 2014 Mar 20;5:e1135. doi: 10.1038/cddis.2014.109.

49.

The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.

De Sanctis F, Sandri S, Ferrarini G, Pagliarello I, Sartoris S, Ugel S, Marigo I, Molon B, Bronte V.

Front Immunol. 2014 Feb 24;5:69. doi: 10.3389/fimmu.2014.00069. eCollection 2014. Review.

50.

Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase.

Ruggero K, Guffanti A, Corradin A, Sharma VK, De Bellis G, Corti G, Grassi A, Zanovello P, Bronte V, Ciminale V, D'Agostino DM.

J Virol. 2014 Apr;88(7):3612-22. doi: 10.1128/JVI.02823-13. Epub 2014 Jan 8.

Supplemental Content

Loading ...
Support Center